نتائج البحث - Victoria Landolfi

  • يعرض 1 - 9 نتائج من 9
تنقيح النتائج
  1. 1
    Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial

    Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial حسب Lee-Jah Chang, Ya Meng, Helene Janosczyk, Victoria Landolfi, H. Keipp Talbot

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Safety and Immunogenicity of an Inactivated Quadrivalent Influenza Vaccine in Children 6 Months through 8 Years of Age

    Safety and Immunogenicity of an Inactivated Quadrivalent Influenza Vaccine in Children 6 Months through 8 Years of Age حسب David P. Greenberg, Corwin A. Robertson, Victoria Landolfi, Amitabha Bhaumik, Shelly Senders, Michael D. Decker

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

    Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial حسب Andrew J. Dunning, Carlos A. DiazGranados, Timothy Voloshen, Branda Hu, Victoria Landolfi, H. Keipp Talbot

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty

    Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty حسب Carlos A. DiazGranados, Andrew J. Dunning, Corwin A. Robertson, H. Keipp Talbot, Victoria Landolfi, David P. Greenberg

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines

    Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines حسب Carlos A. DiazGranados, Corwin A. Robertson, H. Keipp Talbot, Victoria Landolfi, Andrew J. Dunning, David P. Greenberg

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial

    Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial حسب Peter H. Tsang, Geoffrey J. Gorse, Cynthia Strout, Malcolm Sperling, David P. Greenberg, Ayca Ozol-Godfrey, Carlos A. DiazGranados, Victoria Landolfi

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

    Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults حسب Carlos A. DiazGranados, Andrew J. Dunning, Murray Kimmel, Daniel Kirby, John J. Treanor, Avi Collins, Richard Pollak, Janet Christoff, John Earl, Victoria Landolfi, Earl E Martin, Sanjay Gurunathan, Richard Nathan, David P. Greenberg, Nadia Tornieporth, Michael D. Decker, H. Keipp Talbot

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza

    Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza حسب Sudha Chivukula, Timothy Plitnik, Timothy Tibbitts, Shrirang Karve, Anusha Dias, Donghui Zhang, Rebecca Goldman, Hardip Gopani, Asad Khanmohammed, Ashish Sarode, Dustin L. Cooper, Heesik Yoon, Younghoon Kim, Yanhua Yan, Sophia T. Mundle, Rachel Groppo, Adrien Beauvais, Jinrong Zhang, Natalie G. Anosova, Charles Pin‐Kuang Lai, Lu Li, Gregory Ulinski, Peter Piepenhagen, Joshua M. DiNapoli, Kirill V. Kalnin, Victoria Landolfi, Ron Swearingen, Tong‐Ming Fu, Frank DeRosa, Danilo R. Casimiro

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models

    Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models حسب Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Jinrong Zhang, Donghui Zhang, Adrien Beauvais, Natalie G. Anosova, Tim Tibbitts, Joshua M. DiNapoli, Gregory Ulinski, Peter Piepenhagen, Sheila M. Cummings, Dinesh S. Bangari, Susan Ryan, Po-Wei Huang, James W. Huleatt, Deanne Vincent, Katherine Fries, Shrirang Karve, Rebecca Goldman, Hardip Gopani, Anusha Dias, Khang Tran, Minnie Zacharia, Xiaobo Gu, Lianne Boeglin, Jonathan Abysalh, Jorel Vargas, Angela Beaulieu, Monic Shah, Travis Jeannotte, Kimberly Gillis, Sudha Chivukula, Ron Swearingen, Victoria Landolfi, Tong‐Ming Fu, Frank DeRosa, Danilo R. Casimiro

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: